DEDICATED TOPIC - DOSE OF RECORD
PT-141 Dosage Research in Women
The dose written on the label, the doses tested in trials, and why none of that is a recommendation to any individual.
Before the details
When people search for PT-141 dosage for women, they usually want the number on the label. Here it is, as a documented fact: the approved product is 1.75 mg, injected just under the skin, used only as needed — no more than one dose in 24 hours and no more than eight doses in a month, taken at least 45 minutes before anticipated activity [7]. That is the dose of record from the U.S. prescribing information, not advice for any person.
Why the cap matters: the label limits frequency partly because more-frequent dosing raises the risk of skin darkening and is where appetite and blood-pressure effects become more relevant [7]. The trials that earned the approval used exactly this 1.75 mg as-needed dose [3]. Earlier studies tested a few other strengths to find that dose. This page describes what was studied and what the label says — it does not tell anyone what to take, and nothing here is a personal recommendation.
PT-141 dosage for women: the dose of record
The authoritative figure is the prescribing information. For the approved HSDD indication in premenopausal women, the dose is 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated sexual activity, with a hard ceiling of one dose per 24 hours and eight doses per month [7]. This is the dose carried verbatim through both pivotal trials [3].
The pharmacology behind the schedule: after a subcutaneous dose, peak blood concentration is reached in a median of about 0.5–1.0 hours, and the drug clears with a terminal half-life of roughly 2.7 hours (range 1.9–4.0 h) [7]. That short window is consistent with an as-needed, event-driven product rather than a daily one. The label also documents a volume of distribution near 25 L, clearance around 6.5 L/hr, and excretion that is roughly 65% renal and 23% fecal [7].
What the dose-finding studies tested
The 1.75 mg figure did not appear from nowhere. Phase 2 subcutaneous dose-finding work in women evaluated 0.75, 1.25, and 1.75 mg before the highest of those was carried into the Phase 3 program [7]. The approval ultimately rested on the 1.75 mg dose in the two RECONNECT trials [3].
It is worth separating this from unrelated dosing in other research lines. High-frequency Phase 1 metabolic protocols in women used subcutaneous doses up to 2.5 mg, up to three times daily for 15 days — but that was a research protocol probing appetite and weight effects, never an approved or sexual-function use, and it is exactly the high-frequency pattern the label's frequency cap is designed to avoid [7]. Describing it here is context, not endorsement; nothing on this page is a human-dosing recommendation.
Why no number here is advice
Two reasons make the distinction sharp for PT-141. First, the approved product is a prescription drug carrying a contraindication — it is not to be used by people with uncontrolled high blood pressure or known cardiovascular disease, because of documented transient blood-pressure rises [7]. A label dose assumes that screening has happened. Second, material sold as "PT-141 research chemical" has no verified identity, purity, or concentration, so a number printed on a vial of it means little [7].
This digest therefore reports the label dose and the studied doses as facts of record and stops there. It recommends no dose to any individual, for any use, by any route. For the broader pharmacokinetics and the routes that have been studied, see the full PT-141 dosage page.